Please select the option that best describes you:
In which patients with SSc do you add anti-platelet therapy and/or statins for Raynaud's phenomenon?
This question is part of our collaboration with ACR Convergence 2025 to Continue the Conversation from the meeting. This question was inspired by the session "Challenges & Solutions for Management of Raynaud’s Phenomenon" by Dr. @Tracy M. Frech and Dr. @John Pauling. If you did not attend the meeting, information about Convergence On Demand can be found here.
Answer from: at Community Practice
The evidence for antiplatelet therapy and statins for RP is not strong, mainly owing to the challenges we would face trying to develop a trial that would demonstrate a net benefit of such treatments in a controlled setting. In clinical practice, I consider adding these agents in as adjunct therapies...
Sign In or Register to read more
Answer from: at Academic Institution
We believe that platelet aggregation plays some role in the development of digital ulcers, but we don't have any trial data to support the use of antiplatelet agents. But for patients who have recurrent digital tip ulcerations despite vasodilators, I will consider the use of antiplatelet agents (81 ...